Learning objectives
After this module you should be able to:
- Explain why people with type 2 diabetes carry the highest risk of MASLD-related fibrosis, and why the risk runs in both directions.
- Apply FIB-4 to every adult with type 2 diabetes or prediabetes, and interpret it with attention to age and its limits in diabetes.
- Choose glucose-lowering drugs in a patient with MASLD using EASL, AASLD, global and Saudi positions, including in cirrhosis.
- Set up a simple clinic workflow for testing, cardiovascular protection, monitoring and referral.
Boxed recommendations are paraphrased from the EASL–EASD–EASO 2024 guideline, with its grades: evidence level from 1 (strongest) to 5; recommendation strong, weak or open; consensus is the panel's agreement (strong means at least 95%).
1Why diabetes clinics matter
Type 2 diabetes is the single most important driver of progressive metabolic dysfunction-associated steatotic liver disease (MASLD). A meta-analysis of more than 1.8 million people with type 2 diabetes estimated that 65% had MASLD and 32% had steatohepatitis. Among those with MASLD, 36% had significant fibrosis (F2–F4) and 15% had advanced fibrosis (F3–F4) [1]. In the Middle East and North Africa, the pooled prevalence of MASLD was 68.7% in people with type 2 diabetes, against 39.4% in the general population [2].
Of all metabolic conditions, type 2 diabetes and obesity, especially abdominal obesity, have the largest effect on how MASLD progresses to advanced fibrosis, cirrhosis and liver cancer. [3]
The relationship runs both ways. Diabetes raises the risk of advanced fibrosis five- to six-fold and of hepatocellular carcinoma about 2.5-fold, mainly after more than 10 years of diabetes [4]. In turn, MASLD is linked to a 2.2-fold higher risk of developing diabetes [5]. AASLD therefore advises screening people with diabetes for advanced fibrosis, and screening people with MASLD for diabetes [6].
Most of these patients are seen in primary care and endocrine clinics, where MASLD often goes undiagnosed [4]. These clinics are where advanced fibrosis is found early or missed, and where the bigger killer is managed: MASLD is linked to more non-fatal cardiovascular disease (hazard ratio 1.40) and chronic kidney disease (1.43) [3].
2Who to test and how
Clinicians should actively look for MASLD with fibrosis in adults with type 2 diabetes, in those with abdominal obesity plus at least one more metabolic risk factor, and in those with abnormal liver tests. [3]
All major guidelines agree that type 2 diabetes alone justifies a fibrosis assessment, and that the first test is FIB-4, not ALT or ultrasound [3,6,7]. The American Diabetes Association Standards of Care 2025 advise FIB-4 in adults with type 2 diabetes or prediabetes, and transient elastography (or ELF) when FIB-4 is 1.3 or more (grade B) [8]. Diabetes Canada 2025 makes a similar recommendation (grade B, level 2) [4].
Ultrasound for steatosis is not a useful screening step; in diabetes the question is fibrosis [4,7]. The Saudi consensus agrees, recommends FIB-4 first (93.3% agreement), and extends FIB-4 screening to type 1 diabetes with cardiometabolic risk factors, aminotransferases above 30 U/L or steatosis on imaging [5].
| Guideline | Who to test | After FIB-4 | Repeat if low risk |
|---|---|---|---|
| EASL–EASD–EASO 2024 | Type 2 diabetes; abdominal obesity + ≥1 risk factor; abnormal liver tests | Elastography or ELF | 1–3 years |
| AASLD 2023 | Type 2 diabetes, complicated obesity, family history of cirrhosis | VCTE, MRE or ELF | 1–2 years with diabetes |
| ADA 2025 | Type 2 diabetes or prediabetes | If ≥1.3: VCTE, or ELF | — |
| Diabetes Canada 2025 | All with prediabetes or type 2 diabetes | 1.3–2.67: VCTE or ELF; >2.67: refer | 1–2 years |
| Global consensus 2025 | Type 2 diabetes; obesity + ≥1 risk factor; raised ALT/AST for 6 months | ≥1.3 (≥2.0 at 65+): VCTE | 1–3 years |
| Saudi consensus 2026 | Abdominal obesity + ≥1 risk factor such as diabetes; type 1 diabetes with risk factors | Liver stiffness | LSM <8 kPa: repeat in 2–3 years |
The message is the same everywhere; the details differ [3,6,8,4,7,5].
3Reading FIB-4 in people with diabetes
FIB-4 uses age, AST, ALT and platelets. A value below 1.3 (below 2.0 from age 65) means low risk of advanced fibrosis; 2.67 or more means high risk; values in between are indeterminate [3,7]. Below 1.3, the negative predictive value for advanced fibrosis is about 95% [4]. Module 1 explains the formula, the age-adjusted cut-off and why FIB-4 should not be relied upon under age 35 [9].
Three points matter in diabetes. First, non-invasive tests may perform less well in type 2 diabetes [4]; the Saudi consensus cites a study of 1,115 people with diabetes in which a low FIB-4 still carried a fourfold likelihood of significant or advanced fibrosis [5]. Second, many patients are over 65, where the 2.0 cut-off prevents needless referrals [9,7]. Third, NFS below −1.455 rules out advanced fibrosis about as well with diabetes as without, whereas APRI is less accurate in diabetes [4].
A low FIB-4 is reassuring but not a guarantee. If there are clinical or imaging signs of chronic liver disease, use a second-line test or refer. If ALT or AST stay raised for more than 6 months despite a low FIB-4, look for other causes [8].
4Choosing glucose-lowering drugs when MASLD is present
Choose glucose-lowering drugs for their proven cardiometabolic benefits and, where there is a choice, prefer those that also help the liver. The global consensus names GLP-1 receptor agonists as the preferred treatment for diabetes and obesity in MASH. Pioglitazone, SGLT2 inhibitors and DPP-4 inhibitors can be used for diabetes but not as MASH-targeted therapy; metformin, insulin and sulfonylureas are not preferred [7].
GLP-1 receptor agonists are safe in MASH, including compensated cirrhosis, and should be used for their licensed indications (type 2 diabetes and obesity) because they improve cardiometabolic outcomes. [3]
Pioglitazone is safe in non-cirrhotic MASH where it is available, but large phase III trials have not shown enough histological benefit to recommend it as a MASH-targeted drug. [3]
SGLT2 inhibitors and metformin are safe in MASLD and should be used for diabetes, heart failure and chronic kidney disease, although the evidence is too weak to use them as MASH-targeted drugs. [3]
Incretin-based drugs. EASL lists GLP-1 receptor agonists and co-agonists such as tirzepatide as preferred for diabetes in non-cirrhotic MASLD [3]. In a phase 2 trial in MASH with F2–F3 fibrosis, tirzepatide 15 mg weekly resolved MASH without worsening fibrosis in 62% versus 10% on placebo, and fibrosis improved in about 51–55% across doses versus 30% [5].
Pioglitazone improves steatohepatitis in several randomised trials, without clear fibrosis regression even after 3 years. Weight gain, oedema, bone loss in post-menopausal women and a debated bladder cancer risk limit its use [3], and it can worsen heart failure [6]. Here the guidelines disagree. EASL calls it safe but not MASH-targeted (weak) [3]; AASLD says it can be considered for MASH with diabetes [6]; Diabetes Canada suggests preferring pioglitazone (grade A) or subcutaneous semaglutide (grade D) in diabetes with F2–F3 [4]. The Saudi consensus recommends pioglitazone, usually 15–30 mg daily, for type 2 diabetes with biopsy-proven MASH and advanced fibrosis (80% agreement) [5].
SGLT2 inhibitors reduce liver fat moderately but lack histology trials; their value is heart and kidney protection [3,6]. Metformin does not improve histology [6], but observational data suggest it may improve transplant-free survival in advanced fibrosis or cirrhosis, so do not stop it in cirrhosis unless decompensation or renal failure requires it [3]. DPP-4 inhibitors did not help in phase 2 trials [6]. Observational studies link sulfonylureas (odds ratio 1.62) and insulin (2.61) with more liver cancer, and metformin (0.50) with less; these are associations, not proof of cause [5].
| Drug class | Liver effect | Cardiometabolic and kidney effect | In cirrhosis |
|---|---|---|---|
| GLP-1 receptor agonists | MASH resolution; semaglutide 2.4 mg also improved fibrosis | Weight loss; heart and kidney benefit | Child-Pugh A: yes |
| Tirzepatide | Less liver fat; MASH resolution (phase 2) | Large weight loss | Not addressed |
| Pioglitazone | Improves steatohepatitis; fibrosis effect uncertain | Insulin sensitivity, lipids; weight gain, oedema, heart failure | Not well studied |
| SGLT2 inhibitors | Less liver fat; no histology data | Heart failure and kidney protection | Child-Pugh A–B: yes |
| Metformin | No histological benefit | Glycaemic control | Compensated, eGFR >30: yes; decompensated: no |
| DPP-4 inhibitors | No benefit | Glycaemic control | Not addressed |
| Sulfonylureas | No benefit | Hypoglycaemia risk | Decompensated: avoid |
| Insulin | No benefit | Hypoglycaemia risk | Decompensated: preferred |
Table 2 draws on EASL, AASLD and global consensus data [3,6,10,7]. In cirrhosis, EASL allows GLP-1 receptor agonists in Child-Pugh A and SGLT2 inhibitors in Child-Pugh A and B (weak recommendations), and favours insulin once decompensated [3,7].
Metformin can be continued in compensated cirrhosis with preserved kidney function, but should not be used in decompensated cirrhosis, especially with kidney impairment, because of the risk of lactic acidosis. [3]
Avoid sulfonylureas once the liver has decompensated, because of the risk of hypoglycaemia. [3]
5MASH-targeted drugs in people with diabetes
Semaglutide 2.4 mg. In the phase 3 ESSENCE trial, 72 weeks of semaglutide 2.4 mg weekly resolved MASH without worsening fibrosis in 62.9% of patients versus 34.3% on placebo, and improved fibrosis by at least one stage without worsening MASH in 36.8% versus 22.4%. On this basis the United States FDA gave accelerated approval in August 2025 for MASH with F2–F3 fibrosis [10,11]. AASLD suggests selecting candidates by non-invasive tests, for example VCTE 8–15 kPa or ELF 9.2–10.5 [10].
The dose matters. The liver results come from 2.4 mg weekly; the diabetes formulation (0.5 or 1.0 mg weekly) was approved for cardiovascular risk reduction after SUSTAIN-6, not on liver end points. In diabetes, also watch for retinopathy complications (3.0% versus 1.8% in SUSTAIN-6) in people with known retinopathy during rapid glucose lowering [10].
Without phase III proof of histological benefit, GLP-1 receptor agonists cannot yet be recommended as MASH-targeted drugs. [3]
EASL wrote this in 2024, before ESSENCE; AASLD now gives guidance on semaglutide 2.4 mg for F2–F3 MASH [10], so the two differ. The Saudi consensus recommends GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3 mg daily) with lifestyle change in MASLD with a BMI above 27 kg/m², diabetes or cardiovascular disease (73.3% agreement) [5].
Where it is locally approved and within its label, resmetirom should be considered for adults with non-cirrhotic MASH and significant fibrosis (F2 or more). [3]
Resmetirom is dosed at 100 mg daily from 100 kg body weight and 80 mg below. With it, statin doses should not exceed 20 mg for rosuvastatin or simvastatin and 40 mg for atorvastatin or pravastatin, with lipid monitoring [12]. In MAESTRO-NASH, 14% were on a stable GLP-1 receptor agonist (up to 1 mg weekly) and responded similarly; combination with semaglutide 2.4 mg has not been studied [10]. The Saudi consensus noted that resmetirom was not approved in Saudi Arabia when it was written [5]; always check current SFDA status. Vitamin E is not recommended with diabetes [4,5].
6Heart and kidney protection
Assess cardiovascular risk and related conditions, including diabetes, dyslipidaemia, hypertension, kidney disease and sleep apnoea, in every adult with MASLD. [3]
Cardiovascular disease is the leading cause of death in MASLD, yet statins are under-used: in one cohort only 37% of people with MASLD and cardiovascular disease were on a statin. Fear of liver injury is a common barrier, although severe statin liver injury is exceedingly rare [4]. AASLD calls statins safe and recommended across MASLD, including compensated cirrhosis [6].
Statins can be used in chronic liver disease, including compensated cirrhosis, and should be prescribed according to cardiovascular risk guidelines. [3]
Check blood pressure, creatinine, eGFR and urine albumin at baseline and follow-up [3], and use a formal cardiovascular risk tool [7]. Prefer drugs that protect heart and kidney: SGLT2 inhibitors [3], and semaglutide, which at 1.0 mg weekly cut major kidney and cardiovascular events by 24% in type 2 diabetes with chronic kidney disease (FLOW) [10]. Evidence is too thin to give ACE inhibitors or ARBs for the liver itself; use them for standard kidney and blood pressure indications [4].
7Monitoring and referral
Because MASLD is tied to many cardiometabolic conditions, care should be multidisciplinary so that both liver and non-liver outcomes are targeted. [3]
Low risk (FIB-4 below 1.3, or below 2.0 from 65): manage in the diabetes clinic and repeat FIB-4 every 1–2 years (AASLD, Diabetes Canada) or 1–3 years (EASL, global consensus) [6,4,3,7]. Indeterminate: liver stiffness or ELF, or refer if neither is available [4]. High risk (FIB-4 above 2.67, or a high second-line result): refer to hepatology [4,5].
Second-line thresholds differ. EASL treats 8–12 kPa as a grey zone [3]. The Saudi consensus calls 8–12 kPa intermediate risk and advises referral to a gastroenterologist or hepatologist [5]. Diabetes Canada is the most cautious and refers anyone with liver stiffness of 8 kPa or more or ELF of 7.7 or more [4]. Agree one local rule with your hepatology service and apply it consistently.
Liver cancer surveillance also differs. EASL and the global consensus reserve routine 6-monthly ultrasound, with or without alpha-fetoprotein, for cirrhosis; EASL individualises it at F3, and the global consensus individualises it for all non-cirrhotic patients by risk profile [3,7]. The Saudi consensus advises surveillance when FIB-4 is above 2.67 or liver stiffness above 12 kPa, a lower threshold based on low-level evidence [5]. All people with MASLD should be considered for hepatitis A and B vaccination [7].
8Building a clinic workflow
Pathways work when they are automatic. A UK primary care pathway using FIB-4 then ELF detected five times more advanced fibrosis and cirrhosis and cut unnecessary referrals by 81% [13]. Order AST with ALT and platelets at the annual diabetes review, and have the laboratory or electronic record report FIB-4 automatically.
| Step | Action | Where |
|---|---|---|
| 1 | Adults with type 2 diabetes or prediabetes; type 1 with risk factors | Clinic |
| 2 | Alcohol ≤20 g/day (women) or ≤30 g/day (men) | Clinic |
| 3 | Yearly AST, ALT, platelets; automatic FIB-4 | Laboratory |
| 4 | FIB-4 <1.3 (<2.0 at 65+): repeat in 1–2 years | Clinic |
| 5 | Indeterminate: VCTE or ELF | Elastography |
| 6 | FIB-4 >2.67 or high second-line result: refer | Hepatology |
| 7 | All: statin, blood pressure, kidneys, drug choice (Table 2) | Clinic |
The steps follow the guideline pathways and MASLD alcohol limits [7,4,8].
9Clinical case
A 58-year-old woman with long-standing type 2 diabetes
- Presentation
- Seen in a diabetes centre in Jeddah. Type 2 diabetes for 12 years, on metformin, gliclazide and basal insulin. BMI 34 kg/m², HbA1c 8.6%, eGFR 62 mL/min/1.73 m² with albuminuria. No statin, because a previous doctor worried about her liver. AST 38 U/L, ALT 34 U/L, platelets 165 ×10⁹/L. No alcohol; hepatitis B and C negative.
- Step 1
- FIB-4 = (58 × 38) ÷ (165 × √34) = 2,204 ÷ (165 × 5.83) = 2,204 ÷ 962.1 = 2.29: indeterminate (1.3–2.67) at age 58.
- Step 2
- VCTE (XL probe, fasting): 13.4 kPa, IQR/median 21%. Above 12 kPa (high risk) but below 15 kPa, with platelets above 150: advanced fibrosis is likely and the 10–15 kPa range suggests compensated advanced chronic liver disease; with platelets ≥150, clinically significant portal hypertension is ruled out. She is referred to hepatology.
- Decision
- The diabetes team does not wait. A GLP-1 receptor agonist is started; gliclazide is stopped and basal insulin reduced to avoid hypoglycaemia. An SGLT2 inhibitor and a statin are added; metformin continues. If hepatology confirms F2–F3, semaglutide 2.4 mg or resmetirom may be discussed, subject to current SFDA approval.
- Teaching points
- Age and a low-normal platelet count raised FIB-4 despite normal-range enzymes. The drug changes protect heart, kidneys and liver together, and stopping the sulfonylurea lowers hypoglycaemia risk. The statin was the most overdue treatment.
10Test yourself
Choose an answer to see the explanation. Nothing is recorded.
1. A 49-year-old with type 2 diabetes has normal ALT, AST and liver ultrasound. What should the clinic do?
Diabetes alone justifies FIB-4. Enzymes can be normal in advanced fibrosis, and ultrasound does not stage fibrosis.
2. Which class does the global consensus prefer for diabetes or obesity in MASH?
GLP-1 receptor agonists improve weight, glucose and cardiovascular outcomes and resolved MASH in trials.
3. A patient with diabetes develops decompensated cirrhosis. Which drug should be avoided because of hypoglycaemia?
EASL advises avoiding sulfonylureas after decompensation; insulin is preferred at this stage.
4. Which weekly semaglutide dose produced the ESSENCE histology results?
ESSENCE used 2.4 mg weekly for 72 weeks. The 0.5–1.0 mg diabetes doses were not approved on liver end points.
5. A patient with diabetes, MASLD, compensated cirrhosis and high LDL cholesterol: what about a statin?
Statins are safe in compensated cirrhosis and should be used to lower cardiovascular risk (EASL LoE 1, strong).
11Key messages
- About 7 in 10 people with type 2 diabetes in our region have MASLD; about 1 in 7 with both has advanced fibrosis.
- Calculate FIB-4 in every adult with type 2 diabetes or prediabetes, whatever the enzymes; use 2.0 from age 65.
- Prefer GLP-1 receptor agonists or tirzepatide, and SGLT2 inhibitors; guidelines differ on pioglitazone.
- In cirrhosis, keep metformin only if compensated with adequate eGFR, avoid sulfonylureas after decompensation, and use insulin.
- Statins are safe and under-used; refer high-risk results using one agreed local threshold.
References
- En Li Cho E, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 2023;72(11):2138–48. doi:10.1136/gutjnl-2023-330110
- Younossi ZM, et al. Prevalence of MASLD in the Middle East and North Africa. Liver Int 2024;44(4):1061–70. doi:10.1111/liv.15852
- EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024;81:492–542. doi:10.1016/j.jhep.2024.04.031
- Diabetes Canada Clinical Practice Guidelines Expert Working Group; Kim J, et al. Diabetes and metabolic dysfunction-associated steatotic liver disease in adults: a clinical practice guideline. Can J Diabetes 2025;49(4):222–36. doi:10.1016/j.jcjd.2025.04.003
- Abaalkhail F, et al. MASLD management in Saudi Arabia: a modified Delphi-based adaptation of international standards. Saudi J Gastroenterol 2026;32(2):104–20. doi:10.4103/sjg.sjg_199_25
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of NAFLD. Hepatology 2023;77:1797–835. doi:10.1097/HEP.0000000000000323
- Younossi ZM, et al. Global consensus recommendations for MASLD and MASH. Gastroenterology 2025;169(5):1017–32. doi:10.1053/j.gastro.2025.02.044
- American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl 1):S59–85. doi:10.2337/dc25-S004
- McPherson S, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740–51. doi:10.1038/ajg.2016.453
- Bansal MB, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology 2026;83(5):1326–40. doi:10.1097/HEP.0000000000001608
- Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025;392:2089–99. doi:10.1056/NEJMoa2413258
- Chen VL, et al. Resmetirom therapy for MASLD: October 2024 updates to AASLD Practice Guidance. Hepatology 2025;81(1):312–20. doi:10.1097/HEP.0000000000001112
- Srivastava A, et al. Prospective evaluation of a primary care referral pathway for patients with NAFLD. J Hepatol 2019;71(2):371–8. doi:10.1016/j.jhep.2019.03.033
How to cite this module
Desoky M. MASLD in the diabetes clinic. Metabolic Liver Academy, version 1.0. Updated 2026-10-03. Available from: https://drmahmouddesoky.github.io/metabolic-liver-academy/modules/diabetes-clinic.html
For education only. This module summarises published evidence and guidelines; it does not replace clinical judgement, full guidelines or local drug labels. It is not accredited for CME credit. Disclaimer.